BI Asset Management Fondsmaeglerselskab A S Grows Position in Amgen Inc. $AMGN

BI Asset Management Fondsmaeglerselskab A S raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 12.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 93,366 shares of the medical research company’s stock after acquiring an additional 10,455 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Amgen were worth $26,348,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Howe & Rusling Inc. increased its holdings in shares of Amgen by 6.4% in the 3rd quarter. Howe & Rusling Inc. now owns 5,256 shares of the medical research company’s stock valued at $1,483,000 after purchasing an additional 317 shares in the last quarter. Optimize Financial Inc purchased a new stake in Amgen during the third quarter worth about $421,000. Payne Capital LLC acquired a new position in Amgen during the third quarter worth about $508,000. Lokken Investment Group LLC increased its holdings in Amgen by 3.8% in the third quarter. Lokken Investment Group LLC now owns 5,080 shares of the medical research company’s stock valued at $1,434,000 after buying an additional 184 shares in the last quarter. Finally, Pinnacle West Asset Management Inc. lifted its position in shares of Amgen by 0.5% during the 3rd quarter. Pinnacle West Asset Management Inc. now owns 9,650 shares of the medical research company’s stock valued at $2,723,000 after acquiring an additional 45 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research reports. Daiwa Capital Markets upped their price target on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Piper Sandler raised their price target on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. BMO Capital Markets lifted their price target on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $347.65.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat and company guidance lifted — Amgen reported Q4 EPS and revenue above Street estimates and issued FY‑2026 EPS and revenue guidance that came in around expectations while signaling continued product-volume growth; this is the primary catalyst pushing the stock higher. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
• Positive Sentiment: Goldman Sachs raised its price target to $415 and kept a Buy rating — a high-profile upward revision that signals confidence in Amgen’s growth runway and likely supports further buying interest. Goldman Sachs adjusts price target on Amgen to $415 from $403, maintains Buy
• Positive Sentiment: Portfolio & pipeline momentum — coverage notes highlight double‑digit revenue and EPS growth for 2025 and faster uptake of new Amgen products (including obesity assets) that underpin the company’s guidance and longer‑term upside. Amgen posts double-digit revenue and EPS growth for 2025
• Positive Sentiment: Obesity program and late‑stage data in focus — investors are increasingly oriented toward MariTide/MariTide‑related obesity studies and other pipeline catalysts that could materially add revenue, helping explain enthusiastic flows. AMGN’s Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
• Positive Sentiment: Technical/institutional signal — the stock is trading near 52‑week highs and commentary suggests heavy institutional buying, reinforcing momentum into today’s session. Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $350 but kept a Neutral rating — PT higher but rating unchanged, so limited directional push from this call. Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald
• Neutral Sentiment: Morgan Stanley nudged its target to $309 but kept an Equal‑Weight rating — the firm raised its view slightly but still implies downside vs. the current price, so the call is not uniformly bullish. Morgan Stanley raises price target on Amgen to $309 from $304, keeps Equal-Weight
• Negative Sentiment: Analysts flag execution/legacy‑product risks — some coverage (Citi and others) notes legacy product erosion and execution risks that could temper upside if new products don’t scale as expected. That is the key watch‑out for investors despite today’s positive headlines. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks

Insider Activity at Amgen

In other news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is currently owned by insiders.

Amgen Price Performance

Amgen stock opened at $366.22 on Thursday. The stock has a market capitalization of $197.20 billion, a P/E ratio of 25.74, a P/E/G ratio of 2.98 and a beta of 0.46. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $368.75. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The firm’s 50-day moving average is $333.19 and its two-hundred day moving average is $310.44.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 152.71%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.